Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

December 30, 2023

Study Completion Date

August 1, 2024

Conditions

Biliary Tract CancerImmune Checkpoint InhibitorPredictive Cancer Model

Interventions

DRUG

Immune Checkpoint Inhibitors

Immune Checkpoint Inhibitors including Durvalumab, Pembrolizumab and Toripalimab

Trial Locations (1)

Chinese Academy of Medical Sciences & Peking Union Medical College Hospital (CAMS&PUMCH), Beijing

All Listed Sponsors

collaborator

Geneplus-Beijing Co. Ltd.

INDUSTRY

lead

Peking Union Medical College Hospital

OTHER